Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Violetta V. Leshchenko, Pei Yu Kuo, Rita Shaknovich, David T. Yang, Tobias Gellen, Adam Petrich, Yiting Yu, Yvonne Remache, Marc A. Weniger, Sarwish Rafiq, K. Stephen Suh, Andre Goy, Wyndham Wilson, Amit K. Verma, Ira Braunschweig, Natarajan Muthusamy, Brad S. Kahl, John C. Byrd, Adrian Wiestner, Ari MelnickSamir Parekh

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a mostly incurable malignancy arising from naive B cells (NBCs) in the mantle zone of lymph nodes. We analyzed genomewide methylation in MCL patients with the HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR) assay and found significant aberrancy in promoter methylation patterns compared with normal NBCs. Using biologic and statistical criteria, we further identified 4 hypermethylated genes CDKN2B, MLF-1, PCDH8, and HOXD8 and 4 hypomethylated genes CD37, HDAC1, NOTCH1, and CDK5 when aberrant methylation was associated with inverse changes in mRNA levels. Immunohistochemical analysis of an independent cohort of MCL patient samples confirmed CD37 surface expression in 93% of patients, validating its selection as a target for MCL therapy. Treatment of MCL cell lines with a small modular immunopharmaceutical (CD37-SMIP) resulted in significant loss of viability in cell lines with intense surface CD37 expression. Treatment of MCL cell lines with the DNA methyltransferase inhibitor decitabine resulted in reversal of aberrant hypermethylation and synergized with the histone deacetylase inhibitor suberoylanilide hydroxamic acid in induction of the hypermethylated genes and anti-MCL cytotoxicity. Our data show prominent and aberrant promoter methylation in MCL and suggest that differentially methylated genes can be targeted for therapeutic benefit in MCL.

Original languageEnglish (US)
Pages (from-to)1025-1034
Number of pages10
JournalBlood
Volume116
Issue number7
DOIs
StatePublished - Aug 19 2010

Fingerprint

Mantle-Cell Lymphoma
Methylation
DNA Methylation
Genes
Cells
decitabine
Pharmaceutical Preparations
Histone Deacetylase Inhibitors
Methyltransferases
Cytotoxicity
Cell Line
Assays
B-Lymphocytes
Messenger RNA
DNA
Cell- and Tissue-Based Therapy
Ligation
Cohort Studies
Therapeutics
Lymph Nodes

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Leshchenko, V. V., Kuo, P. Y., Shaknovich, R., Yang, D. T., Gellen, T., Petrich, A., ... Parekh, S. (2010). Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 116(7), 1025-1034. https://doi.org/10.1182/blood-2009-12-257485

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. / Leshchenko, Violetta V.; Kuo, Pei Yu; Shaknovich, Rita; Yang, David T.; Gellen, Tobias; Petrich, Adam; Yu, Yiting; Remache, Yvonne; Weniger, Marc A.; Rafiq, Sarwish; Suh, K. Stephen; Goy, Andre; Wilson, Wyndham; Verma, Amit K.; Braunschweig, Ira; Muthusamy, Natarajan; Kahl, Brad S.; Byrd, John C.; Wiestner, Adrian; Melnick, Ari; Parekh, Samir.

In: Blood, Vol. 116, No. 7, 19.08.2010, p. 1025-1034.

Research output: Contribution to journalArticle

Leshchenko, VV, Kuo, PY, Shaknovich, R, Yang, DT, Gellen, T, Petrich, A, Yu, Y, Remache, Y, Weniger, MA, Rafiq, S, Suh, KS, Goy, A, Wilson, W, Verma, AK, Braunschweig, I, Muthusamy, N, Kahl, BS, Byrd, JC, Wiestner, A, Melnick, A & Parekh, S 2010, 'Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma', Blood, vol. 116, no. 7, pp. 1025-1034. https://doi.org/10.1182/blood-2009-12-257485
Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 2010 Aug 19;116(7):1025-1034. https://doi.org/10.1182/blood-2009-12-257485
Leshchenko, Violetta V. ; Kuo, Pei Yu ; Shaknovich, Rita ; Yang, David T. ; Gellen, Tobias ; Petrich, Adam ; Yu, Yiting ; Remache, Yvonne ; Weniger, Marc A. ; Rafiq, Sarwish ; Suh, K. Stephen ; Goy, Andre ; Wilson, Wyndham ; Verma, Amit K. ; Braunschweig, Ira ; Muthusamy, Natarajan ; Kahl, Brad S. ; Byrd, John C. ; Wiestner, Adrian ; Melnick, Ari ; Parekh, Samir. / Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. In: Blood. 2010 ; Vol. 116, No. 7. pp. 1025-1034.
@article{10ad94a1f68e4ec6b95e11ec52cd19ea,
title = "Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) is a mostly incurable malignancy arising from naive B cells (NBCs) in the mantle zone of lymph nodes. We analyzed genomewide methylation in MCL patients with the HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR) assay and found significant aberrancy in promoter methylation patterns compared with normal NBCs. Using biologic and statistical criteria, we further identified 4 hypermethylated genes CDKN2B, MLF-1, PCDH8, and HOXD8 and 4 hypomethylated genes CD37, HDAC1, NOTCH1, and CDK5 when aberrant methylation was associated with inverse changes in mRNA levels. Immunohistochemical analysis of an independent cohort of MCL patient samples confirmed CD37 surface expression in 93{\%} of patients, validating its selection as a target for MCL therapy. Treatment of MCL cell lines with a small modular immunopharmaceutical (CD37-SMIP) resulted in significant loss of viability in cell lines with intense surface CD37 expression. Treatment of MCL cell lines with the DNA methyltransferase inhibitor decitabine resulted in reversal of aberrant hypermethylation and synergized with the histone deacetylase inhibitor suberoylanilide hydroxamic acid in induction of the hypermethylated genes and anti-MCL cytotoxicity. Our data show prominent and aberrant promoter methylation in MCL and suggest that differentially methylated genes can be targeted for therapeutic benefit in MCL.",
author = "Leshchenko, {Violetta V.} and Kuo, {Pei Yu} and Rita Shaknovich and Yang, {David T.} and Tobias Gellen and Adam Petrich and Yiting Yu and Yvonne Remache and Weniger, {Marc A.} and Sarwish Rafiq and Suh, {K. Stephen} and Andre Goy and Wyndham Wilson and Verma, {Amit K.} and Ira Braunschweig and Natarajan Muthusamy and Kahl, {Brad S.} and Byrd, {John C.} and Adrian Wiestner and Ari Melnick and Samir Parekh",
year = "2010",
month = "8",
day = "19",
doi = "10.1182/blood-2009-12-257485",
language = "English (US)",
volume = "116",
pages = "1025--1034",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

AU - Leshchenko, Violetta V.

AU - Kuo, Pei Yu

AU - Shaknovich, Rita

AU - Yang, David T.

AU - Gellen, Tobias

AU - Petrich, Adam

AU - Yu, Yiting

AU - Remache, Yvonne

AU - Weniger, Marc A.

AU - Rafiq, Sarwish

AU - Suh, K. Stephen

AU - Goy, Andre

AU - Wilson, Wyndham

AU - Verma, Amit K.

AU - Braunschweig, Ira

AU - Muthusamy, Natarajan

AU - Kahl, Brad S.

AU - Byrd, John C.

AU - Wiestner, Adrian

AU - Melnick, Ari

AU - Parekh, Samir

PY - 2010/8/19

Y1 - 2010/8/19

N2 - Mantle cell lymphoma (MCL) is a mostly incurable malignancy arising from naive B cells (NBCs) in the mantle zone of lymph nodes. We analyzed genomewide methylation in MCL patients with the HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR) assay and found significant aberrancy in promoter methylation patterns compared with normal NBCs. Using biologic and statistical criteria, we further identified 4 hypermethylated genes CDKN2B, MLF-1, PCDH8, and HOXD8 and 4 hypomethylated genes CD37, HDAC1, NOTCH1, and CDK5 when aberrant methylation was associated with inverse changes in mRNA levels. Immunohistochemical analysis of an independent cohort of MCL patient samples confirmed CD37 surface expression in 93% of patients, validating its selection as a target for MCL therapy. Treatment of MCL cell lines with a small modular immunopharmaceutical (CD37-SMIP) resulted in significant loss of viability in cell lines with intense surface CD37 expression. Treatment of MCL cell lines with the DNA methyltransferase inhibitor decitabine resulted in reversal of aberrant hypermethylation and synergized with the histone deacetylase inhibitor suberoylanilide hydroxamic acid in induction of the hypermethylated genes and anti-MCL cytotoxicity. Our data show prominent and aberrant promoter methylation in MCL and suggest that differentially methylated genes can be targeted for therapeutic benefit in MCL.

AB - Mantle cell lymphoma (MCL) is a mostly incurable malignancy arising from naive B cells (NBCs) in the mantle zone of lymph nodes. We analyzed genomewide methylation in MCL patients with the HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR) assay and found significant aberrancy in promoter methylation patterns compared with normal NBCs. Using biologic and statistical criteria, we further identified 4 hypermethylated genes CDKN2B, MLF-1, PCDH8, and HOXD8 and 4 hypomethylated genes CD37, HDAC1, NOTCH1, and CDK5 when aberrant methylation was associated with inverse changes in mRNA levels. Immunohistochemical analysis of an independent cohort of MCL patient samples confirmed CD37 surface expression in 93% of patients, validating its selection as a target for MCL therapy. Treatment of MCL cell lines with a small modular immunopharmaceutical (CD37-SMIP) resulted in significant loss of viability in cell lines with intense surface CD37 expression. Treatment of MCL cell lines with the DNA methyltransferase inhibitor decitabine resulted in reversal of aberrant hypermethylation and synergized with the histone deacetylase inhibitor suberoylanilide hydroxamic acid in induction of the hypermethylated genes and anti-MCL cytotoxicity. Our data show prominent and aberrant promoter methylation in MCL and suggest that differentially methylated genes can be targeted for therapeutic benefit in MCL.

UR - http://www.scopus.com/inward/record.url?scp=77956525903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956525903&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-12-257485

DO - 10.1182/blood-2009-12-257485

M3 - Article

C2 - 20427703

AN - SCOPUS:77956525903

VL - 116

SP - 1025

EP - 1034

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -